

---

## **ABATTIS ANNOUNCES A MANUFACTURING PARTNERSHIP WITH EMPIRICAL LABS OF FT. COLLINS, COLORADO**

**Vancouver, BC – January 15, 2015 - Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT),** a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announces a manufacturing partnership with Empirical Labs of Ft. Collins, Colorado

This relationship will allow Abattis Bioceuticals Corp the exclusive license for Cannabidiol rich hemp oil products delivered directly to licensed physicians and dispensaries.

Empirical Labs is a high quality nutraceutical manufacturing facility. They specialize in Liposomal delivery of nutrients, a process that improves the absorption of phytochemicals by binding them to beneficial fats. This process will increase the delivery of phytocannabinoids in Abattis Cannabidiol-rich hemp oil from 50% to 90%.

In 1989, Herbalists Kelly and Nazreen Goyen started Empirical Labs. As natural health enthusiasts they used their own experiences in healing to help shape Empirical Labs. Their work towards providing high quality nutraceutical products for doctors and consumers quickly earned them a reputation as having a keen sense of quality when selecting herbs, extracts, vitamins and minerals.

Empirical Labs is managed by Clinical Herbalist, Asa Waldstein who is an American Herbalist Guild member and honors graduate of The Rocky Mountain Center for Botanical Studies (Paul Bergner/Feather Jones). Asa possesses extensive herbal wildcrafting and formulation knowledge and has over 15 years experience managing in the natural products industry.

Dr. Emek Blair Ph.D. oversees our R & D and Quality Assurance. He earned his undergraduate degree from Occidental College and performed his graduate work in bio-analytical Chemistry at the University of California, Irvine. Dr. Blair developed the proprietary and cutting edge liposome technology used at Empirical Labs to formulate and manufacture its highly effective liposomal product line.

### **About Abattis Bioceuticals Corp.**

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug

Suite 1040 – 885 West Georgia St.  
Vancouver, BC V6C 3E8  
Tel: (604) 336.0881  
Email: [news@abattis.com](mailto:news@abattis.com)



---

market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: [www.abattis.com](http://www.abattis.com).

ON BEHALF OF THE BOARD

***"Mike Withrow"***

Michael Withrow, President & CEO

For further information, contact Saf Dhillon, IR for Abattis Bioceuticals Corp. at (604) 568-8868 or at [news@abattis.com](mailto:news@abattis.com).

***NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.***

#### **FORWARD LOOKING INFORMATION**

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on [www.sedar.com](http://www.sedar.com). While the Company may elect to, it does not undertake to update this information at any particular time.